SGLT-2 inhibitor

Phase 3Small molecule

SSheffield Teaching Hospitals NHS Foundation Trust

SGLT-2 inhibitor is one of 156 small molecule programs targeting Type 2 Diabetes. It is currently in Phase 3.

Indications

Total Trials

Active Trials

155

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 DiabetesActive, not recruiting

Lung CancerActive, not recruiting

Duchenne Muscular Dystrophy (DMD)Recruiting

Type 1 DiabetesRecruiting

Coronary Artery DiseaseRecruiting

Type 2 DiabetesPreclinical

Active, not recruiting

Lung CancerPreclinical

Active, not recruiting

Duchenne Muscular Dystrophy (DMD)Phase 1

Recruiting

Type 1 DiabetesPhase 1

Recruiting

Coronary Artery DiseasePhase 3

Recruiting

Competition

Competitive Landscape

206 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Tagrisso

AstraZeneca

Phase 3

19 2

Beyfortus

BeiGene

Phase 3

10 3

Imjudo

AstraZeneca

Phase 3

6 4

Tecentriq

Roche

Phase 3

6 5

Alecensa

Roche

Phase 3

3 6

DATROWAY

Daiichi Sankyo

Phase 3

2 7

Ilaris

Novartis

Phase 3

2 8

Verzenio

Eli Lilly

Phase 3

2 9

Zepzelca

Jazz Pharmaceuticals

Phase 3

2 10

Tarlatamab-Dznl

Amgen

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Lung Cancer

NCT07272057

Q1 2027

Phase 1Recruiting

Type 1 Diabetes

NCT06753994

Q3 2027

Post-ApprovalRecruiting

Kidney Transplant

NCT07143773

Recruiting

Advanced

NCT06905405

Q1 2028

Phase 1Recruiting

Duchenne Muscular Dystrophy (DMD)

NCT07172971

Clinical

Trials by Indication[1]

Type 2 Diabetes2 trials

Hydroxyl Free Radical Associated Effects of SGLT-2 Inhibitors in Type 2 Diabetes

Completed·UUniversity of Pecs··NCT06797115·40 enrolled

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

Active, not recruiting·MMaryAnn Banerji·Phase 4·NCT07325435·60 enrolled

Lung Cancer1 trial

SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes

Not yet recruiting·SShanghai Chest Hospital·N/A·NCT07272057·200 enrolled

Renal insufficiency1 trial

SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency

Terminated·PPeking University People's Hospital·Phase 4·NCT05737186·11 enrolled

Advanced1 trial

The Use of Advanced Imaging in HFpEF

Recruiting·SSheffield Teaching Hospitals NHS Foundation Trust··NCT06905405·40 enrolled

Diabetic Ketoacidosis1 trial

Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors

Not yet recruiting·—·Phase 2·NCT07421518·75 enrolled

5 more indications

Type 1 Diabetes1 trial

Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors

Recruiting·MMcGill University·Phase 1·NCT06753994·24 enrolled

Kidney Transplant1 trial

SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients

Recruiting·OOdense University Hospital·Phase 4·NCT07143773·88 enrolled

Coronary Artery Disease1 trial

DELayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected aetiologY (DELAY-HF), Pilot Study

Recruiting·KKyungsub Song·Approved·NCT07572032·80 enrolled

Duchenne Muscular Dystrophy (DMD)1 trial

duCHennE caRdiomyopathy mItigation Sglt2 inHibitor

Recruiting·LLarry W. Markham·Phase 1·NCT07172971·10 enrolled

Unspecified1 trial

SGLT2i and Incretin and CRTd.

Completed·UUniversity of Campania Luigi Vanvitelli·Phase 4·NCT03282136·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for SGLT-2 inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SGLT-2 inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SGLT-2 inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sheffield Teaching Hospitals NHS Foundation Trust company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSheffield Teaching Hospitals NHS Foundation Trust

SGLT-2 inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q1 2028

Trials by Indication[1]

Type 2 Diabetes2 trials

Lung Cancer1 trial

Renal insufficiency1 trial

Advanced1 trial

Diabetic Ketoacidosis1 trial

Type 1 Diabetes1 trial

Kidney Transplant1 trial

Coronary Artery Disease1 trial

Duchenne Muscular Dystrophy (DMD)1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News